848 results on '"Cooper, Nichola"'
Search Results
2. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
3. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
4. Evaluating the clinical validity of genes related to hemostasis and thrombosis using the Clinical Genome Resource gene curation framework
5. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
6. The role of CD8+ T-cell clones in immune thrombocytopenia
7. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
8. Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation
9. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)
10. Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells
11. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
12. Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in COVID-19
13. Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro
14. Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia
15. Bone marrow remodeling supports hematopoiesis in response to immune thrombocytopenia progression in mice
16. Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study
17. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
18. International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee
19. Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration
20. Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease
21. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia
22. Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial
23. Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review
24. Safety and efficacy of SARS‐CoV‐2 vaccination in patients with immune thrombocytopenia: A two‐centre review
25. Evaluating the clinical validity of genes related to hemostasis and thrombosis using the ClinGen gene curation framework
26. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial
27. American Society of Hematology 2019 guidelines for immune thrombocytopenia
28. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders
29. Updated international consensus report on the investigation and management of primary immune thrombocytopenia
30. Blockchain Introduced
31. Emerging Markets
32. Refugees and Humanitarian Settings
33. Blockchain for Universal Health Coverage
34. Transforming Cities
35. Can Blockchain Really Help the Poor?
36. Blockchain, the Digital State, and the New World Order
37. Donors and International Organisations
38. The role of Protein Kinase Cα in the skin and cutaneous wound healing
39. Management of immune thrombocytopenia in elderly patients
40. Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial.
41. Safety and efficacy of SARS‐CoV‐2 vaccination in patients with immune thrombocytopenia: A two‐centre review.
42. PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
43. PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
44. P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
45. P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
46. PB2552: VAYHIA: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF IANALUMAB VS PLACEBO IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA THAT FAILED ≥1 LINE OF TREATMENT
47. PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
48. TECHNOLOGY AND HEALTHCARE OPPORTUNITIES IN EMERGING MARKETS
49. Immune Thrombocytopenia: Where Are We Now?
50. Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.